Document is current
Any future updates will be listed below
-
Authors
Ferrández, Maria C. https://orcid.org/0009-0007-6084-5266
Wiegers, Sanne E.
Zwezerijnen, Gerben J. C.
Heymans, Martijn W.
Lugtenburg, Pieternella J.
Eertink, Jakoba J.
Kurch, Lars
Hüttmann, Andreas
Hanoun, Christine
Dührsen, Ulrich
Barrington, Sally F.
Mikhaeel, N. George
Ceriani, Luca
Zucca, Emanuele
Czibor, Sándor
Györke, Tamás
Chamuleau, Martine E. D.
Zijlstra, Josée M.
Boellaard, Ronald
Golla, Sandeep S. V.
-
Funding
Funding for this research was provided by:
Hanarth Fonds (Hanarth Fonds)
KWF Kankerbestrijding (#VU-2018-11648)
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 25 October 2025
First Online: 28 November 2025
Declarations
:
: All individual participants included in the study gave written informed consent to participate in the study. The HOVON-84 study was approved by the institutional review board of the Erasmus MC (2007–055) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Not applicable.
: Not applicable.
: This work was financially supported by the Hanarth Fonds Fund and the Dutch Cancer Society (#VU-2018-11648). M.C.F., S.S.V.G, S.C.A.V., J.J.E., S.E.W., G.J.C.Z., M.W.H. and R.B. declare no competing financial interests. P.J.L. received research funding from Takeda, Servier and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, Incyte and AbbVie. J.M.Z. received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, BMS and Roche. No other potential conflicts of interest relevant to this article exist.
